Actively Recruiting
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
Led by Fred Hutchinson Cancer Center · Updated on 2026-04-20
50
Participants Needed
1
Research Sites
118 weeks
Total Duration
On this page
Sponsors
F
Fred Hutchinson Cancer Center
Lead Sponsor
R
Rising Tide Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.
CONDITIONS
Official Title
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Ability to understand and willing to sign informed consent
- Clinical diagnosis of IgA monoclonal gammopathy of undetermined significance (MGUS) based on IMWG-2014 criteria
- Agree to use adequate contraception during the study (women of child-bearing potential and men during and one month after treatment)
- No antibiotic use in the preceding 2 weeks
You will not qualify if you...
- Receiving other investigational agents
- Pregnant women
- Known hypersensitivity to rifaximin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
M
Madhav Dhodapkar, MBBS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here